Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q4 FY23 results · Jan–Mar 2023
Natco Pharma reported revenue from operations of ₹897.90 crore (up 50.5% from Q4 FY22) and net profit of ₹275.80 crore for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 897.90 | 596.80 | +50.5% | 492.50 | +82.3% |
| Other income | 29.00 | 13.80 | +110.1% | 20.80 | +39.4% |
| Total income | 926.90 | 610.60 | +51.8% | 513.30 | +80.6% |
| Profit before tax | 324.40 | (49.60) | Turned profit | 81.40 | +298.5% |
| Net profit for the period | 275.80 | (50.50) | Turned profit | 62.30 | +342.7% |
| EPS, basic (₹) | 15.11 | (2.77) | Turned profit | 3.41 | +343.1% |
| Net margin (%) | 30.7 | -8.5 | 12.6 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 781.20 | 514.10 | +52.0% | 413.00 | +89.2% |
| Other income | 17.50 | 10.40 | +68.3% | 18.60 | −5.9% |
| Total income | 798.70 | 524.50 | +52.3% | 431.60 | +85.1% |
| Profit before tax | 306.40 | (67.10) | Turned profit | 45.00 | +580.9% |
| Net profit for the period | 254.10 | (61.30) | Turned profit | 37.30 | +581.2% |
| EPS, basic (₹) | 13.92 | (3.36) | Turned profit | 2.04 | +582.4% |
| Net margin (%) | 32.5 | -11.9 | 9.0 |
Consolidated
- Filed with BSE
- 29 May 2023, 22:06 IST
- Board meeting
- 29 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 May 2023, 22:06 IST
- Board meeting
- 29 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE